Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis-Reference-Cited by-同舟云学术

Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis

Published:2015-11-04 Issue:12 Volume:12 Page:4434-4444
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Good David J.¹,Hartley Ruiling¹,Mathias Neil¹,Crison John¹,Tirucherai Giridhar²,Timmins Peter³,Hussain Munir¹,Haddadin Raja¹,Koo Otilia¹,Nikfar Faranak¹,Fung Nga Kit Eliza⁴

Affiliation:

1. Drug Product Science and Technology, Bristol-Myers Squibb, New Brunswick, New Jersey 08903, United States

2. Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States

3. Drug Product Science and Technology, Bristol-Myers Squibb, Moreton, U.K.

4. Bioanalytical Sciences, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States

Funder

Bristol-Myers Squibb

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.5b00624

Reference25 articles.

1. Challenges and New Technologies of Oral Controlled Release

2. Hydrophilic Matrix Tablets for Oral Controlled Release

3. Oxybutynin extended release for the management of overactive bladder: a clinical review

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Silico Modeling Approaches Coupled with In Vitro Characterization in Predicting In Vivo Performance of Drug Delivery System Formulations;Molecular Pharmaceutics;2023-07-31

2. Strategies for Managing Solid Form Transformation Risk in Drug Product;Journal of Pharmaceutical Sciences;2023-04

3. The Application of Biopharmaceutics Classification Systems to Modified‐Release Formulations;Oral Drug Delivery for Modified Release Formulations;2022-04-08

4. Applications of PBPK/PBBM modeling in generic product development: An industry perspective;Journal of Drug Delivery Science and Technology;2022-03

5. Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products;The AAPS Journal;2020-07-27